August Moretti compensation by year
4D Molecular Therapeutics Summary Compensation Table · all 3 fiscal years held| Component | FY2019 | FY2020 | FY2021 |
|---|---|---|---|
| Salary | $374,242 | $399,712 | $435,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $1,661,243 | $0 | $2,048,585 |
| Non-equity incentive | $89,725 | $220,050 | $139,200 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,500 | $13,000 | $13,000 |
| Total | $2,137,710 | $632,762 | $2,635,785 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 4D Molecular Therapeutics, Inc. DEF 14A filed April 13, 2022, accession 0001193125-22-104263, and prior-year filings. Open the filing on EDGAR.
How this page was built: the 4D Molecular Therapeutics, Inc. filed document, accession 0001193125-22-104263. Every figure is read from that document and cited to the page and table it appears in. Filed April 13, 2022.
Equity holdings
unvested awards at FY2021 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| Option | 60,954 | — | $9.41 |
| Option | 56,875 | — | $41.66 |
Per the Outstanding Equity Awards at Fiscal Year-End table in 4D Molecular Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
3 Form 4 lines since the FY2021 proxy (filed April 13, 2022)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2023-05-15 | Exercise or conversion | — | 3,000 | $9.41 | 11,045 |
| 2023-05-15 | Exercise or conversion derivative | — | 3,000 | $0.00 | 217,060 |
| 2023-02-10 | Grant or award derivative | — | 50,000 | $0.00 | 50,000 |
The 3 most recent of 3 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
4D Molecular Therapeutics’s named executive officers, FY2021
as the company reported each| Named executive officer | Role | FY2021 total |
|---|---|---|
| David Kirn | Chief Executive Officer | $5,200,825 |
| August Moretti · this page | Chief Financial Officer | $2,635,785 |
| Theresa Janke | Chief of Staff | $2,572,695 |
The full 4D Molecular Therapeutics compensation record
free company briefThis page is one person within 4D Molecular Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 4D Molecular Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.